Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Low-fat diet helps genetically predisposed animals avoid liver cancer

Low-fat diet helps genetically predisposed animals avoid liver cancer

June 12, 2009

Penn study could lead to screening methods to detect precancerous conditions and cancer prevention strategies related to obesity

PHILADELPHIA - In a study comparing two strains of mice, one susceptible to developing cancer and the other not, researchers found that a high-fat diet predisposed the cancer-susceptible strain to liver cancer, and that by switching to a low-fat diet early in the experiment, the same high-risk mice avoided the malignancy. The switched mice were lean rather than obese and had healthy livers at the end of the study.




The findings, from a joint University of Pennsylvania School of Medicine and Case Western Reserve University study, appear online this month in Human Molecular Genetics.

The investigators studied hepatocellular carcinoma (HCC), a type of liver cancer that is one of the leading causes of cancer death worldwide. Thirty percent of cases of this type of liver cancer are associated with obesity, type 2 diabetes, and related metabolic diseases, although a direct link between these and liver cell cancer has not been completely established. "The connection between obesity and cancer is not well understood at this point," says senior co-author John Lambris, PhD, the Dr. Ralph and Sallie Weaver Professor of Research Medicine at Penn. The researchers hope the results will lead to the development of blood tests that can detect precancerous conditions related to diet.

The remaining seventy percent of HCC cases result from hepatitis B and C viral infections, exposure to the fungal toxin aflatoxin, chronic alcohol use, or genetic liver diseases.

The usual outcome of hepatocellular carcinoma is poor, because only 10 to 20 percent of these tumors can be surgically removed. If the cancer cannot be completely removed, the disease is usually deadly within 3 to 6 months. Hepatocellular carcinoma causes close to 700,000 deaths worldwide per year, mostly outside the US.

The researchers tested the long-term effects of high-fat and low-fat diets on males of two inbred strains of mice and discovered that one strain, named C57BL/6J, was susceptible to non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma on a high-fat, but not a low-fat diet. The other strain, called A/J, was not susceptible to disease on a high-fat diet. The mice were fed their respective diets for close to 500 days, weighed periodically, and then analyzed for the presence of disease.

RNA profiles of hepatocellular carcinoma versus tumor-free liver tissue at the end of the experiment showed that two signaling networks - one centered on Myc and the other on NF-kappa B - were involved. This result is similar to findings obtained from studies on the two major classes of hepatocellular carcinoma in humans.

At the end of the experiment, mice susceptible to cancer showed characteristics of NASH such as inflammation and fibrosis, and, in some cases, cirrhosis as well as hepatocellular carcinoma, in their livers. A switch from a high-fat to a low-fat diet reversed these outcomes in groups of C57BL/6J mice that were fed a high-fat diet early in the experiment. The switched C57BL/6J mice were lean rather than obese and had healthy livers at the end of the study. All mice kept on a high-fat diet for the duration of the experiment had liver tumors at the end of 500 days.

A similar change in diet may have important implications for preventing liver cancers in humans, suggest the researchers. "The reason these findings are so provocative is that it relates to diet and we now have a unique model we know will develop cancer," says Lambris.

"By waiting for evidence of disease before terminating the study, instead of using an arbitrary endpoint as is done in most experimental studies, we were able to discover an important new experimental model for a common cancer in humans," says senior co-author Joseph Nadeau, Professor and Chair of the Department of Genetics at Case Western Reserve University School of Medicine.

University of Pennsylvania School of Medicine



Related Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News Articles Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News RSS Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News RSS
Promising novel treatment for human cancer -- Chrysanthemum indicum extract
A series of studies have demonstrated that Chrysanthemum indicum possesses antimicrobial, antiinflammatory, immunomodulatory, and neuroprotective effects.

M. D. Anderson examines use of toad venom in cancer treatment
Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

HBV genotype B/B3 and C/C1 are the major genotypes in Indonesia?
Previous studies revealed that HBV genotypes as well as mutations in the core promoter, precore or HBx gene have been shown to have an association with the clinical outcome of liver disease, however, this is still controversial.

Sequential TACE and cryosurgery can improve survival times for patients with HCC?
Hepatocellular carcinoma (HCC)--a liver cancer--is recognized as one of the most common cancers in the world that disproportionately affects Southeast Asians and Africans.

Is RTA a new potential option for the treatment of hydatid cysts?
Current treatment of cystic echinococcosis is surgery or percutaneous aspiration, injection and reaspiration (PAIR) using hypertonic saline or ethanol.

Targeting Tumor Behavior May Lead To New Liver Cancer Drugs
Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior.

What is the relationship between hepatocellular carcinoma and type 2 diabetes mellitus?
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related deaths.

Study indicates cancer preventive effect for statins
The commonly used prescription statin drugs may have a protective effect in the prevention of liver cancer and lead to a reduction in the need for gallbladder removals, according to two studies published in Gastroenterologyiption statin drugs may have a protective effect in the prevention of liver cancer and lead to a reduction in the need for gallbladder removals, according to two studies published in Gastroenterology.

Is telmisartan effective in treating non-alcoholic steatohepatitis?
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

Targeting the protein AEG1 impairs human liver cancer growth in mice
Hepatocellular carcinoma (HCC) is a highly aggressive form of liver cancer and one of the 5 most common cancers worldwide. Devanand Sarkar and colleagues, at Virginia Commonwealth University School of Medicine, Richmond, have now identified a gene that is expressed at high levels in human HCC tumor samples and generates a protein important for HCC progression.
More Hepatocellular Carcinoma Current Events and Hepatocellular Carcinoma News Articles
Hepatocellular Carcinoma

Hepatocellular Carcinoma
by W. Y. Lau (Author), W. Y. Lau (Editor)

This essential book is a compendium of papers written by an international team of world-renowned experts, who cover topics in their respective areas of expertise. Presenting the most up-to-date knowledge of hepatocellular carcinoma, it covers all topics -- including those more controversial ones -- in this rapidly advancing field, from epidemiology to prevention, from molecular biology to gross pathology, from screening to atypical presentation, from diagnosis to treatment, and from assessment to choice of appropriate treatment. This volume is therefore an important contribution to the field of hepatocellular carcinoma.

Contents: Epidemiology (T Y-M Leong & A S-Y Leong); Assessment of Liver Function (D V Mann); Prevention (M C Kew); Screening (M Sherman); Tumor Markers (J Y H...

  Surgsat: Professional Video Journal in General Surgery Volume II: 11:21 Liver Resection for Hepatocellular Carcinoma, 11:22 Operative Treatment of Cancer of the Colon, 11:23-24 The Technique of Total Thyroidectomy

c1986 Video tape. John L. Cameron, M.D., editor. The John Hopkins Medical Institutions. CME-SAT.

5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences - 2007- DVD1

5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences - 2007- DVD1
Also With: The University of Texas - MD Anderson Cancer Center (Host)

DVD 01- Treatment of HCC Yesterday and Today Surgery for HCC: an Eastern Perspective M. Makuuchi, MD Surgery for HCC: a Western Perspective J. Belgheti, MD Interstitial Therapy for HCC T. Livraghi, MD

Hepatocellular Carcinoma: Diagnosis and Treatment (Current Clinical Oncology)

Hepatocellular Carcinoma: Diagnosis and Treatment (Current Clinical Oncology)
by Brian I. Carr (Editor)

Hepatocellular cancer is the fifth most common cancer, with 600,000 new cases reported each year worldwide. Additionally, exciting changes in the science of HCC in the last four years have turned the practice of diagnosing and treating the disease upside down. In Hepatocellular Carcinoma: Diagnosis and Treatment, Second Edition, the leading experts in the field of HCC thoroughly update and expand upon the critically acclaimed first edition with all the latest developments in the diagnosis and treatment of primary liver cancer. The book details for physicians the diagnostic and therapeutic decision making process for dealing with such problems as incidental tumors in the liver transplant, the role of neo-adjuvant chemotherapy, intra-arterial vs intravenous therapy, the uses of...

Diagnosis and Treatment of Hepatocellular Carcinoma

Diagnosis and Treatment of Hepatocellular Carcinoma
by Tito Livraghi (Editor), Masatoshi Makuuchi (Editor), Luigi Buscarini (Editor)

The book is edited by a multidisciplinary team, with an international group of contributors. After discussing the basic and clinical aspects of HCC the main focus of the book is on diagnosis and therapy. The book is both authoritative and practical, providing expert guidance on the various techniques used in diagnosis, such as ultrasound, CT and MRI and the appropriate therapeutic options, for example, surgical resection, transcatheter therapies and radiofrequency ablation. It is fully illustrated throughout in both colour and black and white.

5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences - 2007 DVD 03

5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences - 2007 DVD 03

Symposium: Large HCC (> 5cm) Chairpersons: J. Belgethi, S.A. Curley, W.C. Chapman Surgical Resection J. N. Vauthey Liver Transplantation in Patients with and without Chronic Liver Disease P. Neuhaus Nonsurgical Treatment T. W T. Leung

  Spontaneous regression of hepatocellular carcinoma: potential promise for the future.: An article from: Southern Medical Journal
by Harsha Gadadhar Vardhana (Author), Mukta Panda (Author)

This digital document is an article from Southern Medical Journal, published by Thomson Gale on February 1, 2007. The length of the article is 541 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Spontaneous regression of hepatocellular carcinoma: potential promise for the future.
Author: Harsha Gadadhar Vardhana
Publication: Southern Medical Journal (Magazine/Journal)
Date: February 1, 2007
Publisher: Thomson Gale
Volume: 100 Issue: 2 Page: 223(2)

Distributed by Thomson...

5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences 2007- DVD 02

5th International Meeting Hepatocellular Carcinoma- Eastern and Western Experiences 2007- DVD 02
Also With: The University of Texas - MD Anderson Cancer Center (Host)

Symposium: Early HCC (< 2cm) Chairpersons: M. Makuuchi, C. Charnsangavej, K.Ahrar Imaging of Dysplastic Nodules and Early HCC B. Taouli,MD Dysplastic Nodules vs. Early HCC: The Eastern Perspective M. Kojiro, MD Dysplastic Nodules vs. Early HCC: The Western Perspective G.Y. Lauwers, MD Therapy: Resection, Radiofrequency Ablation, or Transplantation T. Takayama, MD

p53 Mutations in hepatocellular carcinoma patients in Egypt [An article from: International Journal of Hygiene and Environmental Health]

p53 Mutations in hepatocellular carcinoma patients in Egypt [An article from: International Journal of Hygiene and Environmental Health]
by S.A. El-Kafrawy (Author), M. Abdel-Hamid (Author), M. El-Daly (Author), Nada (Author)

This digital document is a journal article from International Journal of Hygiene and Environmental Health, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
The p53 gene plays a major role in hepatocellular carcinoma (HCC). Acquired mutations may provide clues to etiology, as some carcinogenic agents are associated with specific genetic changes in p53. Our aim was to analyze the spectrum of p53 mutations in tumor tissues from subjects with HCC in Egypt, where there is a rising incidence of HCC due to hepatitis C virus (HCV). We collected tumor tissues from 41 subjects with HCC diagnosed at the National Cancer Institute of Cairo...

  Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine.( alkaloids)(Clinical report): An ... Journal of Phytotherapy & Phytopharmacology
by X.-N. Wang (Author), X. Han (Author), L.-N. Xu (Author), L.-H. Yin (Author), Y.-W. Xu (Author), Y. Qi (Author), J.-Y. Peng (Author)

This digital document is an article from Phytomedicine: International Journal of Phytotherapy & Phytopharmacology, published by Urban & Fischer Verlag on December 1, 2008. The length of the article is 3665 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: Enhancement of apoptosis of human hepatocellular carcinoma SMMC-7721 cells through synergy of berberine and evodiamine.( alkaloids)(Clinical report)
Author: X.-N. Wang
Publication: Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Magazine/Journal)
Date: December 1, 2008
Publisher: Urban & Fischer Verlag
Volume: 15 Issue:...

© 2009 BrightSurf.com